Bolasterone

Bolasterone is a synthetic and orally active anabolic–androgenic steroid (AAS) and a 17α-alkylated derivative of testosterone that was marketed in the United States in the 1960s. It is a controlled substance in many countries and is not approved by the Food and Drug Administration (FDA) for medical use.

History

Bolasterone was first described in the literature in 1959. It was developed by the pharmaceutical company Upjohn and was marketed in the United States in the 1960s under the brand name Myagen. The drug was withdrawn from the market in the 1970s due to concerns about its potential for hepatotoxicity.

Pharmacology

As an AAS, bolasterone is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and dihydrotestosterone (DHT). It has strong anabolic effects and moderate androgenic effects, which make it useful for building muscle mass in athletes and bodybuilders.

Side effects

The side effects of bolasterone are similar to those of other AAS. These may include acne, alopecia (hair loss), gynecomastia (breast development in men), virilization in women, and aggression and mood changes in both sexes. More serious side effects may include liver damage, cardiovascular disease, and hypogonadism (reduced function of the gonads).

Legal status

Bolasterone is a controlled substance in many countries, including the United States, Canada, and the United Kingdom. It is classified as a Schedule III drug under the Controlled Substances Act in the United States.

See also

• List of androgens/anabolic steroids
• List of Schedule III drugs (US)

Bolasterone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia